Inhibitors of SARS-CoV-2 Entry: Current and Future Opportunities.
J Med Chem
; 63(21): 12256-12274, 2020 11 12.
Article
in English
| MEDLINE | ID: covidwho-598389
ABSTRACT
Recently, a novel coronavirus initially designated 2019-nCoV but now termed SARS-CoV-2 has emerged and raised global concerns due to its virulence. SARS-CoV-2 is the etiological agent of "coronavirus disease 2019", abbreviated to COVID-19, which despite only being identified at the very end of 2019, has now been classified as a pandemic by the World Health Organization (WHO). At this time, no specific prophylactic or postexposure therapy for COVID-19 are currently available. Viral entry is the first step in the SARS-CoV-2 lifecycle and is mediated by the trimeric spike protein. Being the first stage in infection, entry of SARS-CoV-2 into host cells is an extremely attractive therapeutic intervention point. Within this review, we highlight therapeutic intervention strategies for anti-SARS-CoV, MERS-CoV, and other coronaviruses and speculate upon future directions for SARS-CoV-2 entry inhibitor designs.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Antiviral Agents
/
Virus Internalization
/
SARS-CoV-2
/
COVID-19 Drug Treatment
Type of study:
Etiology study
Limits:
Animals
/
Humans
Language:
English
Journal:
J Med Chem
Journal subject:
Chemistry
Year:
2020
Document Type:
Article
Affiliation country:
Acs.jmedchem.0c00502
Similar
MEDLINE
...
LILACS
LIS